SCHEMBL4065012

SCHEMBL4065012

Cc1ccc(CNc2ncnc3cc(-c4ccc(F)cc4)sc23)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.66
NPC1 O15118 1/20 0.64
RAB9A P51151 1/20 0.64
THRB P10828 1/20 0.52
KIT P10721 5/20 0.52
USP10 Q14694 1/20 0.51
PIK3C3 Q8NEB9 1/20 0.51
USP13 Q92995 1/20 0.51
EGFR P00533 4/20 0.51
TUBB4A P04350 1/20 0.51
TUBB P07437 1/20 0.51
TUBA3C P0DPH7 1/20 0.51
TUBA1B P68363 1/20 0.51
TUBA4A P68366 1/20 0.51
TUBB4B P68371 1/20 0.51
TUBB3 Q13509 1/20 0.51
TUBB2A Q13885 1/20 0.51
TUBB8 Q3ZCM7 1/20 0.51
TUBA3E Q6PEY2 1/20 0.51
TUBA1A Q71U36 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4066184 0.88 FLT1 (0.56) TYK2NPC1RAB9AEGFRTUBB4A
SCHEMBL4071062 0.88 TYK2 (0.62) TYK2NPC1RAB9AKITUSP10
SCHEMBL4069276 0.88 TYK2 (0.62) TYK2NPC1RAB9AKITUSP10
SCHEMBL4069374 0.86 CLK4 (0.53) TYK2NPC1RAB9AEGFRTUBB4A
SCHEMBL13957677 0.84 NPC1 (0.51) TYK2NPC1RAB9AEGFRTUBB4A
SCHEMBL13961313 0.84 NPC1 (0.62) TYK2NPC1RAB9AKITUSP10
SCHEMBL4071318 0.83 EGFR (0.52) TYK2NPC1RAB9AEGFRTUBB4A
SCHEMBL4066624 0.81 PDE5A (0.63) LMNAKDM4EALDH1A1CLK4
SCHEMBL4068415 0.81 PDE5A (0.57) TYK2NPC1RAB9ALMNAKDM4E
SCHEMBL4068541 0.80 FLT1 (0.48) NPC1RAB9AEGFRTUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 TYK2 1012/4885NPC1 3333/4885RAB9A 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.